. . . . . . . "[Because our recent clinical observations indicate that insulin resistance may be an environmental risk factor or disease modifier ('second hit'), we suggest that PPARgamma-activating agents might be beneficial in the future treatment of both insulin-resistant and insulin-sensitive PAH patients with or without BMP-RII mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en . . . . . "2017-02-19"^^ . . "Gene-disease associations inferred from text-mining the literature."@en . "DisGeNET evidence - LITERATURE"@en . "2017-10-17T13:15:34+02:00"^^ . . . . . . . . . . . "v5.0.0.0" . "v5.0.0" .